<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04583605</url>
  </required_header>
  <id_info>
    <org_study_id>MR004</org_study_id>
    <nct_id>NCT04583605</nct_id>
  </id_info>
  <brief_title>The Aim of This Study is to Demonstrat That Vacuum-assisted Closure Versus Conventional Wound Closure Enables to Diminish Local Complications After Lymph Node Dissection in Patients With Metastatic Skin Tumors</brief_title>
  <official_title>Does PREVENA Vacuum-assisted Closure Reduce Lymphorrhoea Compared to Conventional Wound Closure After Axillary and Inguinal Lymph Node Dissection in the Management of Metastatic Cutaneous Skin Tumors ?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, we compared a negative pressure wound therapy, versus a conventional dressing&#xD;
      in order to evaluate the most efficient wound therapy closure after axillary and inguinal&#xD;
      lymph nodes dissections in the management of metastatic skin tumors. A vacuum assisted&#xD;
      closure therapy should prevent these comorbidities.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lymphorrhoea, lymphedema and lymphocyte are significant and common complications after&#xD;
      axillary and inguinal lymph nodes dissections. A vacuum assisted closure therapy should&#xD;
      prevent these comorbidities. In this study, we compared PREVENA, a negative pressure wound&#xD;
      therapy, versus conventional dressings. We evaluated the wound complications at the seventh&#xD;
      day, the thirtieth day and at this end of the first year after surgery. It is a retrospective&#xD;
      study of about ninety lymph nodes dissections among with there were seventy times the use of&#xD;
      a negative pressure wound therapy, PREVENA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 1, 2014</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Actual">September 13, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Is there a visible scar disunion ?</measure>
    <time_frame>between day 1 and day 7, between day 7 and day 30, between day 30 and first year end</time_frame>
    <description>Yes if there is a scar opening, no if there isn't</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Is there lymphorrhoea from the scar ?</measure>
    <time_frame>between day 1 and day 7, between day 7 and day 30, between day 30 and first year end</time_frame>
    <description>Yes if there is lymph coming from the the scar, no if there isn't.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Are there lymphocele punctures ?</measure>
    <time_frame>between day 1 and day 7, between day 7 and day 30, between day 30 and first year end</time_frame>
    <description>Yes if there is any lymphocele puncture, no if there isn't</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Is there any lymphoedema ?</measure>
    <time_frame>between day 1 and day 7, between day 7 and day 30, between day 30 and first year end</time_frame>
    <description>Yes if there is arm or leg lymphoedema, no if there isn't</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">90</enrollment>
  <condition>Melanoma</condition>
  <condition>Skin Cancer</condition>
  <condition>Epidermoid Carcinoma</condition>
  <condition>Neuroendocrine Carcinoma</condition>
  <condition>Lymph Node Metastases</condition>
  <arm_group>
    <arm_group_label>PREVENA</arm_group_label>
    <description>A vacuum wound closure therapy like PREVENA is applied after axillary or inguinal lymph node dissection in the management of metastatic skin tumors</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NON PREVENA</arm_group_label>
    <description>A conventional wound closure is applied after axillary or inguinal lymph node dissection in the management of metastatic skin tumors</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PREVENA</intervention_name>
    <description>A negative pressure wound closure therapy is used after lymph node dissection</description>
    <arm_group_label>PREVENA</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        major patient affected by a metastatic skin tumors&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  major patient affected by a metastatic skin tumors&#xD;
&#xD;
          -  the primitive skin tumor is either a m√©lanoma, either squamous cell carcinoma , or a&#xD;
             neuroendocrine tumor&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  lymph node dissection resumption&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manuela PEREZ</last_name>
    <role>Study Director</role>
    <affiliation>Visceral Surgery Department</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHRU</name>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 20, 2020</study_first_submitted>
  <study_first_submitted_qc>October 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2020</study_first_posted>
  <last_update_submitted>October 6, 2020</last_update_submitted>
  <last_update_submitted_qc>October 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vacuum assisted closure</keyword>
  <keyword>PRENEVA</keyword>
  <keyword>lymph node dissection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Skin Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Neuroendocrine</mesh_term>
    <mesh_term>Lymphatic Metastasis</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

